trial · primary record
cemacabtagene ansegedleucel
Large B-cell Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 250 |
| Primary completion | 2032-12 |
| Primary endpoint | Event-free survival per independent review committee assessment |
| Registry ID | NCT06500273 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:46.378Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06500273
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.